-

Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday, June 20 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). Biocept’s discussion will be hosted by Maxim Group Senior Research Analyst Michael Okunewitch.

Registration information to become an M-Vest member for access to the live and archived presentation webcast is posted to Events & Presentations section of the Biocept website.

About M-Vest

M-Vest is a division of Maxim Group LLC that serves to allows investors access to investment opportunities online and to provide a digital community built for issuers, investors, and thought leaders to share information. The platform provides insights on current market trends through presentations from innovative emerging growth companies and commentary from industry thought leaders via live events and Q&A.

About Biocept

Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Our experts have spent years working to change the way physicians look at cerebrospinal fluid in cancer patients. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, Biocept is a leading commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample.

Contacts

Investor and Media Contact:
Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100

Biocept, Inc.

NASDAQ:BIOC

Release Versions

Contacts

Investor and Media Contact:
Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100

More News From Biocept, Inc.

Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept’s proprietary CNSide assay in monitoring the response to therapy of LM, a c...

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or m...

Biocept to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is ava...
Back to Newsroom